European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer

European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer

Source: 
CP Wire
snippet: 

The Janssen Pharmaceutical Companies of Johnson & Johnson announced on 1/16/19 that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.